Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
MT newswire2026/09/11 08:25Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
04:25 AM EDT, 09/11/2026 (MT Newswires) -- Edwards Lifesciences (EW) said Thursday it has maintained its 2026 financial outlook after US health regulators released an updated national coverage decision for transcatheter aortic valve replacement. The adoption of the revised coverage policy is expected to require time to take effect, the company said. The company plans to share its 2027 and long-term financial projections at an investor conference in December, it said.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Update: Market Chatter: AMD-Backed AI Startup Upstage Weighs Pre-Listing Funding
MT newswire•2026/09/11 16:54
Meta Muse Monetization Seen Limited Near Term, Wedbush Says
MT newswire•2026/09/11 16:53
Market Chatter: Chevron CEO Says Venezuela Oil Sales to Fund Expansion in Country
MT newswire•2026/09/11 16:52
Lucky Strike director Robert J. Bass acquires 600 common shares worth $3,267.60
Reuters•2026/09/11 16:51
